2022 World Conference on Lung Cancer (ePosters)-EP08.01-011. Diabetes Mellitus (DM) is Associated with Poor Outcome in Pembrolizumab-treated Non-Small Cell Lung Cancer (NSCLC) Patients

EP08.01-011. Diabetes Mellitus (DM) is Associated with Poor Outcome in Pembrolizumab-treated Non-Small Cell Lung Cancer (NSCLC) Patients

Back to course

Pdf Summary

A study conducted by Yasmin Leshem et al. aimed to investigate the association between diabetes mellitus (DM) and the outcomes of pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC). Pembrolizumab is an immune checkpoint inhibitor commonly used in the treatment of various cancers. However, the impact of DM on the efficacy of this treatment has not been well explored.<br /><br />The study included 203 NSCLC patients who received pembrolizumab as a first-line treatment either alone or in combination with chemotherapy. The medical records of these patients were reviewed to assess demographic and clinical characteristics, including the presence of pre-treatment DM. Patients who received less than two cycles of treatment were excluded from the analysis.<br /><br />The study found that DM was associated with distinct demographic and clinical characteristics among the NSCLC patients. These included a higher prevalence of hypertension and a higher average body mass index (BMI). However, there was no significant difference in the distribution of oncological treatment based on the presence of DM.<br /><br />Multivariate analysis revealed that DM was an independent risk factor for poor outcomes in NSCLC patients treated with pembrolizumab. Specifically, patients with DM had decreased progression-free survival (PFS) and overall survival (OS) compared to those without DM. Histology, Eastern Cooperative Oncology Group (ECOG) performance status, and treatment type were also found to be significant factors affecting survival outcomes.<br /><br />The findings of this study suggest a potential deleterious effect of DM on the efficacy of pembrolizumab in metastatic NSCLC patients. Further research is needed to confirm these findings in a larger population and to explore similar effects in other types of cancer. Additionally, investigating whether better glycemic control can improve patient outcomes is warranted.

Asset Subtitle

Barliz Waissengrin

Meta Tag

Speaker Barliz Waissengrin

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

diabetes mellitus

pembrolizumab treatment

non-small cell lung cancer

NSCLC

immune checkpoint inhibitor

chemotherapy

hypertension

body mass index

progression-free survival

overall survival